FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807145280> ?p ?o ?g. }

• W2807145280 endingPage "e46" @default.
• W2807145280 startingPage "e46" @default.
• W2807145280 abstract "Objective: Coexistence of hypertension (HTN) and hypercholesterolemia is the major synergistic and modifiable risk factor for cardiovascular disease (CVD). A fixed-dose combination (FDC) of anti-HTN drug and stain may be valuable in terms of improving drug compliance especially for statin. Because renin angiotensin system activation and hypercholesterolemia are accompanied with obesity and angiotensin receptor blocker is more advantageous for Asians as it does not cause dry cough due to the angiotensin converting enzyme inhibitors, FDC of irbesartan and atorvastatin (Rovelito) may improve the treatment success rate. Design and method: Patients with comorbid HTN and hypercholesterolemia were screened for this prospective, observational, descriptive, multi-center, phase IV study. Eligible patients were administered with Rovelito for 3 months. Dose adjustment was allowed per physician's discretion. Primary purpose of this study was to evaluate the variables that affect treatment success rate for blood pressure (BP) and/or LDL-cholesterol (LDL-C). In addition, the compliance with the therapeutic lifestyle modification and the safety of the study drug were evaluated. Results: Among the total of 2,801 patients enrolled in the study, 945 patients were analyzed for clinical efficacy. BP and LDL-C goals were achieved in 813 (86.03%) and 811 (85.82%), respectively. Higher baseline BP and body mass index (BMI) were the factors for poor treatment success rate of BP goal. Baseline LDL-C level, number of concurrent medications and drinking status were the factors for poor treatment success rate for LDL-C goal. Of the total of 945 study participants, 706 (74.71%) reached the both treatment goals BP and LDL-C, diabetes and higher baseline LDL-C levels and number of concurrent medications were the factors for poor treatment success rate for both BP and LDL-C. Adherence with Rovelito was 97.87 ± 6.06% and incidence of AEs was 4.15%. Conclusions: FDC of irbesartan and atorvastatin (Rovelito) can be very helpful for managing patients with both HTN and hypercholesterolemia in Asian perspectives. Poor metabolic profile itself is as well the reason to choose Rovelito as the factor for poor treatment success rate. Therapeutic life style modification still should be underscored even with 75% treatment success rate for both conditions." @default.
• W2807145280 created "2018-06-13" @default.
• W2807145280 creator A5013645342 @default.
• W2807145280 creator A5028443311 @default.
• W2807145280 creator A5028559225 @default.
• W2807145280 creator A5039494604 @default.
• W2807145280 date "2018-06-01" @default.
• W2807145280 modified "2023-09-26" @default.
• W2807145280 title "CONTRIBUTION FACTORS ON ACHIEVEMENT RATE OF TREATMENT GOALS OF BP AND LDL-C BY 3 MONTHS’ THERAPY OF ROVELITO (FIXED DOSE COMBINATION PILL OF IRBESARTAN AND ATORVASTATIN)" @default.
• W2807145280 doi "https://doi.org/10.1097/01.hjh.0000539085.15099.0f" @default.
• W2807145280 hasPublicationYear "2018" @default.
• W2807145280 type Work @default.
• W2807145280 sameAs 2807145280 @default.
• W2807145280 citedByCount "0" @default.
• W2807145280 crossrefType "journal-article" @default.
• W2807145280 hasAuthorship W2807145280A5013645342 @default.
• W2807145280 hasAuthorship W2807145280A5028443311 @default.
• W2807145280 hasAuthorship W2807145280A5028559225 @default.
• W2807145280 hasAuthorship W2807145280A5039494604 @default.
• W2807145280 hasConcept C126322002 @default.
• W2807145280 hasConcept C23131810 @default.
• W2807145280 hasConcept C2776623344 @default.
• W2807145280 hasConcept C2776839432 @default.
• W2807145280 hasConcept C2776999253 @default.
• W2807145280 hasConcept C2777482532 @default.
• W2807145280 hasConcept C2780221984 @default.
• W2807145280 hasConcept C2780259554 @default.
• W2807145280 hasConcept C71924100 @default.
• W2807145280 hasConcept C84393581 @default.
• W2807145280 hasConcept C98274493 @default.
• W2807145280 hasConceptScore W2807145280C126322002 @default.
• W2807145280 hasConceptScore W2807145280C23131810 @default.
• W2807145280 hasConceptScore W2807145280C2776623344 @default.
• W2807145280 hasConceptScore W2807145280C2776839432 @default.
• W2807145280 hasConceptScore W2807145280C2776999253 @default.
• W2807145280 hasConceptScore W2807145280C2777482532 @default.
• W2807145280 hasConceptScore W2807145280C2780221984 @default.
• W2807145280 hasConceptScore W2807145280C2780259554 @default.
• W2807145280 hasConceptScore W2807145280C71924100 @default.
• W2807145280 hasConceptScore W2807145280C84393581 @default.
• W2807145280 hasConceptScore W2807145280C98274493 @default.
• W2807145280 hasIssue "Supplement 1" @default.
• W2807145280 hasLocation W28071452801 @default.
• W2807145280 hasOpenAccess W2807145280 @default.
• W2807145280 hasPrimaryLocation W28071452801 @default.
• W2807145280 hasRelatedWork W132670735 @default.
• W2807145280 hasRelatedWork W2032989631 @default.
• W2807145280 hasRelatedWork W2167966391 @default.
• W2807145280 hasRelatedWork W2485131627 @default.
• W2807145280 hasRelatedWork W2530018226 @default.
• W2807145280 hasRelatedWork W2760703009 @default.
• W2807145280 hasRelatedWork W2766189674 @default.
• W2807145280 hasRelatedWork W2807145280 @default.
• W2807145280 hasRelatedWork W2951015811 @default.
• W2807145280 hasRelatedWork W3109621134 @default.
• W2807145280 hasVolume "36" @default.
• W2807145280 isParatext "false" @default.
• W2807145280 isRetracted "false" @default.
• W2807145280 magId "2807145280" @default.
• W2807145280 workType "article" @default.